Table 1 Competition assay of different drugs with N,N'-ethylene-bis(iodoacetamide) on MDA-MB-231 and their effects on the inhibition of the bisthioalkylation of Cys-239 and Cys-354 of β-tubulin by N,N'-ethylene-bis(iodoacetamide)
Compound | Cellular target (Binding site) | Drug treatment (µM) | Competition assay | Inhibition of EBI binding to β-tubulin |
|---|---|---|---|---|
Dimethylsulfoxide | N/A | 0.5% |
| N/A |
EBI | Tubulin (C-BS) | 100 | N/A | |
Colchicine + EBI | Tubulin (C-BS) | 2.5 | Yes | |
Combretastatin A-4 + EBI | Tubulin (C-BS) | 2.5 | Yes | |
Podophyllotoxin + EBI | Tubulin (C-BS) | 20 | Yes | |
2-Methoxyestradiol + EBI | Tubulin (C-BS) | 100 | Yes | |
Paclitaxel + EBI | β-Tubulin (T-BS) | 5 | Yes | |
Vinblastine + EBI | β-Tubulin (vinca) | 5 | No | |
Vinblastine + EBI | β-Tubulin (vinca) | 100 | No | |
Verapamil + EBI | Voltage-dependent calcium channel | 100 | No | |
Daunorubicin + EBI | Topoisomerase II | 50 | No |
